Ulrich Müller-Sedgwick, MD (Uni Würzburg) PhD (Uni Leipzig), works for the Government of Jersey as consultant psychiatrist & lead clinician for the Adult ADHD & Autism service. He is a member of the Neuroinclusive Jersey Strategy implementation group and the Jersey Disability & Inclusion Advisory Group. From 2017-21 he was the lead clinician for the North London NHS Foundation Trust Adult ADHD Service in North London, where he continues to hold an honorary consultant position. From 2003-17 he was based in Cambridge, where he developed the Adult ADHD Service for Cambridgeshire and Peterborough NHS Foundation Trust and directed an adult ADHD research group at the Department of Psychiatry, University of Cambridge; he continues to be a Visiting Researcher and Life Member of Clare Hall.

In 2024 he was appointed as (inaugural) ADHD Champion by the Royal College of Psychiatrists (RCPsych) and sits on their Psychopharmacology Committee and on the Executive committee of the Neurodevelopmental Psychiatry Special Interest Group. As media spokesperson on ADHD, he has been interviewed on radio (BBC Radio 4 PM, Radio 5 Drive), by national newspapers (Financial Times, Guardian, Telegraph, Times) and magazines (BBC Music, Enable, Good Housekeeping, New Scientist). He is a founding executive committee member (since 2008) and former president (2019-21) of the UK Adult ADHD Network. He has contributed to NICE guidance and the 2025 ADHD taskforce report as member of the Clinical Reference Group. He is a regular speaker at national training events and international scientific conferences. He has published more than 160 book chapters, papers & policy documents (127 on PubMed, >8000 citations, Google/WoS h-index 61/45).

Ulrich comes from and married into another neurodiverse family. In his free time, he enjoys family and outdoor activities, plays the viola in several orchestras (Jersey Camerata, JCC orchestra, JSO) and investigates the link between musical creativity and neurodiversity.

Abstract

Pharmacological treatment of substance use disorder with co-morbid attention deficit hyperactivity disorder (ADHD) in adults

Ulrich will provide an update on the latest developments of pharmacological treatments for co-morbid ADHD in substance use disorder.